LEADER 01498nam  2200373Ia 450 
001 9910698826503321
005 20090528151655.0
035   $a(CKB)5470000002397603
035   $a(OCoLC)355680178
035   $a(EXLCZ)995470000002397603
100   $a20090528d2001      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $echanges to an approved application : biological products, human blood and blood components intended for transfusion or for further manufacture
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2001]
215   $ai, 30 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 28, 2009).
300   $a"July 2001".
320   $aIncludes bibliographical references (pages 25-26).
517   $aGuidance for industry 
606   $aBlood$xTransfusion$xGovernment policy$zUnited States
606   $aBlood products$xEvaluation$xGovernment policy$zUnited States
615  0$aBlood$xTransfusion$xGovernment policy
615  0$aBlood products$xEvaluation$xGovernment policy
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698826503321
996   $aGuidance for industry$93434577
997   $aUNINA